ZA200808773B - Stable emulsion formulations - Google Patents

Stable emulsion formulations

Info

Publication number
ZA200808773B
ZA200808773B ZA200808773A ZA200808773A ZA200808773B ZA 200808773 B ZA200808773 B ZA 200808773B ZA 200808773 A ZA200808773 A ZA 200808773A ZA 200808773 A ZA200808773 A ZA 200808773A ZA 200808773 B ZA200808773 B ZA 200808773B
Authority
ZA
South Africa
Prior art keywords
stable emulsion
emulsion formulations
formulations
stable
emulsion
Prior art date
Application number
ZA200808773A
Other languages
English (en)
Inventor
Gore Anuradha
Navratil Anne
Neervannan Seshadri
Christopher W Spancake
Zanon Roger
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of ZA200808773B publication Critical patent/ZA200808773B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
ZA200808773A 2006-04-20 2008-10-14 Stable emulsion formulations ZA200808773B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79382506P 2006-04-20 2006-04-20

Publications (1)

Publication Number Publication Date
ZA200808773B true ZA200808773B (en) 2009-07-29

Family

ID=38537687

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200808773A ZA200808773B (en) 2006-04-20 2008-10-14 Stable emulsion formulations

Country Status (14)

Country Link
US (1) US8779004B2 (pt)
EP (1) EP2010150A2 (pt)
JP (1) JP5199239B2 (pt)
KR (1) KR20080110681A (pt)
CN (1) CN101437490A (pt)
AU (1) AU2007240317B2 (pt)
BR (1) BRPI0710814A2 (pt)
CA (1) CA2648939C (pt)
CR (1) CR10384A (pt)
EA (1) EA200802166A1 (pt)
MX (1) MX2008013339A (pt)
NO (1) NO20084368L (pt)
WO (1) WO2007124465A2 (pt)
ZA (1) ZA200808773B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1746976B1 (en) 2004-05-03 2017-01-11 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery
US20080027052A1 (en) * 2006-07-10 2008-01-31 Sharon Moe Methods for treating cystic kidney disease
WO2008075173A2 (en) * 2006-12-15 2008-06-26 Ruprecht-Karls-Universität Heidelberg Methods for treating podocyte-related disorders
WO2008121386A2 (en) * 2007-03-30 2008-10-09 Amgen Inc. Calcimimetic compounds for use in the treatment of bowel disorders
WO2009121015A2 (en) * 2008-03-28 2009-10-01 Amgen Inc. Methods of treating epithelial injury
JP5468221B2 (ja) * 2008-08-04 2014-04-09 株式会社 メドレックス 難溶性薬物の静注用分散製剤
WO2010042642A1 (en) * 2008-10-08 2010-04-15 Amgen Inc. Calcium receptor modulating agents
WO2011146583A2 (en) * 2010-05-19 2011-11-24 Elan Pharma International Limited Nanoparticulate cinacalcet formulations
WO2012039768A2 (en) * 2010-09-24 2012-03-29 Texas Southern University Itraconazole formulations
US8658676B2 (en) * 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
US20120213855A1 (en) * 2011-02-17 2012-08-23 Cima Labs Inc. Dosage forms for weakly ionizable compounds
KR102143435B1 (ko) 2011-11-30 2020-08-11 쓰리엠 이노베이티브 프로퍼티즈 컴파니 펩티드 치료제 및 아미노산을 포함하는 마이크로니들 장치 및 이의 제조 및 사용 방법
PL2858513T3 (pl) * 2012-06-07 2017-09-29 Cargill, Incorporated Możliwe do pompowania kompozycje tłuszczowe, zastosowanie w paszy i sposób zmniejszenia ich lepkości
US9212209B2 (en) * 2012-07-13 2015-12-15 Indiana University Research And Technology Corporation Screening methods for spinal muscular atrophy
CN102895187B (zh) * 2012-09-13 2015-05-06 西安力邦制药有限公司 注射用本芴醇脂肪乳的制备及其在疟疾治疗中的应用
JP6280557B2 (ja) * 2012-10-24 2018-02-14 カーギル インコーポレイテッド リン脂質含有乳化剤組成物
KR101951933B1 (ko) * 2013-03-12 2019-02-25 주식회사 아리바이오 라이소포스파티딜콜린 또는 이의 유도체를 포함하는 지질나노물질 및 이의 제조방법
CN103142477B (zh) * 2013-04-08 2015-09-30 薛巍 一种缓释秋水仙碱的含纳米载体微乳制剂的制备方法
CN106714787A (zh) * 2014-09-25 2017-05-24 富士胶片株式会社 含丙泊酚的水包油型乳液组合物及其制造方法
MX2017013802A (es) 2015-04-29 2018-08-15 Radius Pharmaceuticals Inc Métodos para tratar el cáncer.
MA42991A (fr) 2015-10-16 2018-08-22 Ipsen Biopharm Ltd Stabilisation de compositions pharmaceutiques de camptothécine
KR101744203B1 (ko) * 2016-01-12 2017-06-20 (주)노터스생명과학 포스파티딜콜린을 유효성분으로 포함하는 신장질환 예방 또는 치료용 약학 조성물
CN105769765A (zh) * 2016-03-22 2016-07-20 辅必成（上海）医药科技有限公司 己酸羟孕酮脂肪乳注射液
KR101898282B1 (ko) * 2016-05-24 2018-09-13 주식회사 고려비엔피 항생제의 서방형 수의학적 조성물 및 이의 제조방법
MX2019007748A (es) 2017-01-05 2019-09-09 Radius Pharmaceuticals Inc Formas polimorficas de rad1901-2hcl.
CN109200024A (zh) * 2017-07-07 2019-01-15 江苏恒瑞医药股份有限公司 西那卡塞药物组合物及其医药用途
CN109953979A (zh) * 2017-12-25 2019-07-02 江苏恒瑞医药股份有限公司 西那卡塞药物组合物及其医药用途
SG11202013177WA (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl
KR102158824B1 (ko) * 2018-09-27 2020-09-23 한국화학연구원 자가미세유화 약물전달시스템을 이용한 난용성 약물의 약학적 제제
WO2020093069A1 (en) * 2018-11-02 2020-05-07 Ampersand Biopharmaceuticals, Inc. Management of risk of cation overload and electrolyte imbalance with topically applied buffers
US11992483B2 (en) 2021-03-31 2024-05-28 Cali Biosciences Us, Llc Emulsions for local anesthetics

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR511940A (fr) 1916-12-08 1921-01-07 Rene Emile Trottier Dispositif pour la commande des appareils destinés au classement ou à la séparation des matières solides de tous genres
JPS60258110A (ja) * 1984-06-05 1985-12-20 Daigo Eiyou Kagaku Kk 静脈注射可能なプロゲステロン乳化注射液
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5858684A (en) 1991-08-23 1999-01-12 The Brigham And Women's Hospital, Inc. Method of screening calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
WO1993004373A1 (en) 1991-08-23 1993-03-04 Nps Pharmaceuticals, Inc. Calcium receptor active molecules
CN1192011C (zh) 1991-08-23 2005-03-09 Nps药物有限公司 对钙受体具活性的芳烷基胺化合物
US5763569A (en) 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US6001884A (en) 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5688938A (en) 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
KR100296899B1 (ko) 1993-02-23 2001-10-24 쉘비 칼베르그 모르스 칼슘수용체활성분자
US5962314A (en) 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
BRPI9509411B8 (pt) 1994-10-21 2021-07-06 Nps Pharma Inc composto modulador de receptor de íon inorgânico e composição farmacêutica
EP1258471B1 (en) 1996-05-01 2007-01-24 Nps Pharmaceuticals, Inc. Inorganic ion receptor-active compounds
ES2201300T3 (es) 1996-05-01 2004-03-16 Nps Pharmaceuticals, Inc. Compuestos activos frente a receptores de iones inorganicos.
EP0933354B1 (en) 1996-07-08 2011-03-30 Kyowa Hakko Kirin Co., Ltd. Calcium receptor-active compounds
TW483881B (en) 1996-12-03 2002-04-21 Nps Pharma Inc Calcilytic compounds
NZ503513A (en) * 1997-09-18 2004-12-24 Skyepharma Inc Sustained-release liposomal anesthetic compositions
US6146659A (en) 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
DE69912441T2 (de) 1998-08-19 2004-08-19 Skyepharma Canada Inc., Verdun Injizierbare wässerige propofoldispersionen
JP2002527414A (ja) 1998-10-14 2002-08-27 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド １，２−ジ置換シクロプロパン
FR2800735B1 (fr) 1999-11-09 2002-02-01 Centre Nat Rech Scient Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
US6726919B2 (en) 2000-06-16 2004-04-27 Rtp Pharma, Inc. Injectable dispersion of propofol
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
ATE411275T1 (de) 2000-08-11 2008-10-15 Japan Tobacco Inc Calciumrezeptor-antagonisten
FR2820136A1 (fr) 2001-01-26 2002-08-02 Aventis Pharma Sa Nouveaux derives de l'uree, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
US6908935B2 (en) * 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US7176322B2 (en) 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
EP1572113B1 (en) 2002-08-26 2017-05-17 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof
US20050101576A1 (en) 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
WO2004052354A1 (ja) * 2002-12-06 2004-06-24 Otsuka Pharmaceutical Factory, Inc. プロポフォール含有脂肪乳剤
CL2004000868A1 (es) 2003-04-23 2005-01-21 Japan Tobacco Inc Compuestos derivados de acidos carboxilicos, antagonistas del receptor de calcio 8casr); composiciones farmaceuticas que comprenden el compuesto, utiles para el tratamiento de osteoporosis.
CN1225242C (zh) 2003-05-21 2005-11-02 浙江天皇药业有限公司 一种抗肿瘤药物毛兰素脂肪乳剂及其制备方法
WO2004106280A1 (ja) 2003-05-28 2004-12-09 Japan Tobacco Inc. ＣａＳＲアンタゴニスト
ES2332514T3 (es) * 2003-07-23 2010-02-08 Theravance, Inc. Composiciones farmaceuticas de un agente hipnotico sedante de accion corta.
EP1858553A2 (en) 2005-03-17 2007-11-28 Amgen Inc., Methods of decreasing calcification
FR2885129B1 (fr) * 2005-04-29 2007-06-15 Proskelia Sas Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
US7585886B2 (en) 2005-05-19 2009-09-08 Astellas Pharma Inc. Pyrrolidine derivative or salt thereof
US8486381B2 (en) 2005-09-02 2013-07-16 Amgen Inc. Methods of modulating intestinal fluid balance
WO2008075173A2 (en) 2006-12-15 2008-06-26 Ruprecht-Karls-Universität Heidelberg Methods for treating podocyte-related disorders

Also Published As

Publication number Publication date
KR20080110681A (ko) 2008-12-18
CA2648939C (en) 2014-07-08
WO2007124465A3 (en) 2008-04-10
CR10384A (es) 2008-11-11
US8779004B2 (en) 2014-07-15
US20070249520A1 (en) 2007-10-25
NO20084368L (no) 2008-11-17
EA200802166A1 (ru) 2009-06-30
MX2008013339A (es) 2009-01-26
CA2648939A1 (en) 2007-11-01
AU2007240317A1 (en) 2007-11-01
WO2007124465A2 (en) 2007-11-01
EP2010150A2 (en) 2009-01-07
BRPI0710814A2 (pt) 2011-08-16
JP2009534425A (ja) 2009-09-24
AU2007240317B2 (en) 2012-11-29
CN101437490A (zh) 2009-05-20
JP5199239B2 (ja) 2013-05-15

Similar Documents

Publication Publication Date Title
ZA200808773B (en) Stable emulsion formulations
GB2435419B (en) Formulations
EP2046930A4 (en) FORMULATIONS BASED ON RHAMNOLIPIDS
ZA200901595B (en) Pickering emulsion formulations
ZA200901479B (en) Pickering emulsion formulations
GB0605780D0 (en) Formulations
EP2068886A4 (en) FORMULATIONS CONTAINING A LIPID
PT1986606T (pt) Formulações líquidas contendo fenilefrina
PT1978929T (pt) Emulsão
GB0608098D0 (en) Formulation
HK1134245A1 (en) Multiple emulsion compositions
EP1988922A4 (en) PROTEIN FORMULATIONS
GB0618697D0 (en) Formulations
IL186673A0 (en) Stable emulsion composition
IL197927A0 (en) W/o/w emulsion composition
GB0610336D0 (en) Formulations
GB0615108D0 (en) Novel formulations
GB0625312D0 (en) Formulation
GB0625095D0 (en) Formulation
GB0710899D0 (en) Formulations
IL198160A0 (en) Pharmaceutical formulations
GB0612809D0 (en) Formulation
GB0614393D0 (en) Perfume Formulation
GB0718404D0 (en) Formulations
ZA200807682B (en) Novel formulations